Genelux
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2625 Townsgate Rd Ste 230, Westlake Vill...Phone Number
(805) 267-9889Website
www.genelux.comRevenue
<$5 MillionStock Symbol
GNLXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Genelux
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Geneluxs most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE platform from which Genelux has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.Explore more
Genelux Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Genelux your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Genelux is spiking on competitors!
Genelux, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Genelux has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Genelux has new funding data
Click to see if Genelux had a recent Job posting/layoffs
Product Launch: Get notified when Genelux launches new products
Congratulate Masked Content for being promoted to Masked Content at Genelux
Earning: See what the market has to say on Genelux recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Genelux as Masked Content
Find 3 more new buyers
Compare Similar Companies to Genelux
Compare insights from companies similar to Genelux, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
11-50
Private
-
2004
Yasuo UrataFounder & President & CEO, Oncolys Biopharma Inc & Oncolys Inc Chairman & CEO (USA)
Company Profile Activity
Activity Insights
Genelux is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Genelux is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Genelux.
Genelux financials insights
Gather financial insights about Genelux, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Debt
$20M
Genelux Tech Stack
A closer look at the technologies used by Genelux
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Project
Genelux has announced that its lead program Olvebak addresses safety issues of first-generation viral therapies, can be administered through systemic or intraperitoneal delivery, and has shown a broad spectrum of activity with no maximum tolerated dose reached in over 150 patients treated across various indications.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals
Genelux News & Media
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 --Genelux Corporation to Participate in Upcoming Conferences
WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences.Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
WESTLAKE VILLAGE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat hosted by Boris Peaker, PhD, Managing Director and Senior Equity Research Analyst at Titan Partners, on Monday, January 19, 2026 at 9:00 a.m. PT.Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Genelux
Sign Up For FreeTo access detailed company insights
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Geneluxs most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccin... Read More
